Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: 18-month Results from a Phase 1 Study (P9-3.007)
Claire Henchcliffe(University of California, Irvine), Viviane Tabar(Memorial Sloan Kettering Cancer Center), Suneil K. Kalia(University Health Network), Harini Sarva(Cornell University), Alfonso Fasano(University of Toronto), Ahmed Enayetallah, Andrés M. Lozano(University of Toronto), Antoine Lampron, Cameron Brennan(Memorial Sloan Kettering Cancer Center), W. Stemple, Marcus Yountz, Nauman Abid, Kenny Yu(Memorial Sloan Kettering Cancer Center)
Cited by 0
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Deep Brain Stimulation for Treatment-Resistant Depression
|Neuron|2005|4.1k
Molecular characterization of the tumor microenvironment in breast cancer
|Cancer Cell|2004|1.3k
Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
|Biological Psychiatry|2008|1k